Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | SCN4A | P35499 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | ILK | Q13418 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | FBP1 | P09467 | 1/20 | 0.32 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.32 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27052004 | 0.85 | SMN1; SMN2 (0.46) | SMN1; SMN2CYP3A4RAB9ANPC1SCN4A | |
| SCHEMBL27051974 | 0.84 | ILK (0.41) | SMN1; SMN2CYP3A4RAB9ANPC1SCN4A | |
| SCHEMBL27051994 | 0.84 | SMN1; SMN2 (0.47) | SMN1; SMN2CYP3A4RAB9ANPC1SCN4A | |
| SCHEMBL10333789 | 0.84 | SMN1; SMN2 (0.41) | SMN1; SMN2CYP3A4RAB9ANPC1SCN4A | |
| SCHEMBL27052015 | 0.80 | HSD17B10 (0.42) | SMN1; SMN2CYP3A4RAB9ANPC1SCN4A | |
| SCHEMBL27052005 | 0.78 | SMN1; SMN2 (0.41) | SMN1; SMN2CYP3A4RAB9ANPC1SCN4A | |
| SCHEMBL27051917 | 0.77 | ALDH1A1 (0.46) | SMN1; SMN2CYP3A4RAB9ANPC1SCN4A | |
| SCHEMBL27052011 | 0.76 | SMN1; SMN2 (0.39) | SMN1; SMN2CYP3A4RAB9ANPC1SCN4A | |
| SCHEMBL27052003 | 0.76 | SMN1; SMN2 (0.39) | SMN1; SMN2CYP3A4RAB9ANPC1SCN4A | |
| SCHEMBL27051983 | 0.74 | SMN1; SMN2 (0.41) | SMN1; SMN2CYP3A4RAB9ANPC1SCN4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025918-A1 | KRAS G12D Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20240025918-A1 | KRAS G12D Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025918-A1 | KRAS G12D Inhibitors | KRAS, NRAS, HRAS | SMN1; SMN2 3857/4885CYP3A4 3711/4885RAB9A 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.